https://doi.org/10.1002/14651858.CD015391
Cochrane disclaims all liability and responsibility arising from any reliance placed on this supplementary material which has been supplied by the author(s). The above associated publication’s Author Licence will apply in respect of any supplemental materials published. How to cite the supplementary material is defined in the Cochrane policy.
Study | Reason for exclusion |
Assanovich 2021 |
Ineligible study design: a description of properties of fluvoxamine |
Brown University 2021 |
Ineligible study design: not original study publication, rather a commentary on how fluvoxamine may limit deterioration from COVID-19 |
Glebov 2021 |
Ineligible study design: a highlight of protective effect of fluvoxamine antidepressant against COVID-19, highlighting therapeutic and prophylactic potential |
Hashimoto 2021 |
Ineligible study design: a commentary on mechanisms of action of fluvoxamine for COVID-19 |
Khosravi 2022 |
Ineligible study design: a narrative review |
Marcec 2021 |
Ineligible study design: description of fluvoxamine mechanisms of action and potential use in COVID-19 treatment |
McCarthy 2021 |
Ineligible study design: paper reviewed the pleiotropic properties of fluvoxamine and explored how the drug may be used to treat the inflammatory sequelae of COVID-19 in the future |
Medical Letter 2021 |
Ineligible study design: a commentary on properties of fluvoxamine |
Murchu 2021 |
Ineligible study design: not an original publication |
NCT04711863 |
Suspended Trial: trial was suspended due to closure of the main treatment centre |
Seftel 2021 |
Ineligible study design: a prospective cohort study in real-world experience using fluvoxamine |
Sukhatme 2021 |
Ineligible study design: description of fluvoxamine mechanisms of action and potential use in COVID-19 treatment |